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Introduction
This paper assesses the potential demand for and strategic use of an HIV-1 vaccine in southern India.1 The paper assesses the size of potential high-and low-risk target groups for an HIV-1 vaccine in the 117 districts of Andhra Pradesh, Maharasthra, Karnataka, and Tamil Nadu. It also discusses potential strategies for delivery of the vaccine, prioritization for vaccination, and the political economy of such a vaccine in India. The latter issue includes a discussion of the current level of knowledge and existing level of stigma as barriers to demand for a vaccine, even if it were offered free of charge. In reviewing these data, the paper draws from examples of coverage of prevention programs targeting both high-and low-risk groups, of adoption of other vaccines in India and current levels of spending on them. An HIV-1 vaccine will greatly reduce HIV/AIDS in India, but it will not be a panacea. There will be a continued need for effective prevention programs to guard against behavior reversals or an imperfect vaccine.
The HIV-1 Epidemic in Southern India
The Indian government estimates that in 2000, 3.86 million Indians were living with HIV-1, the second largest number of infected people after South Africa (NACO 2000) . While HIV is transmitted via all major modes of transmission in India, the engine of the Indian epidemic is heterosexual transmission from vulnerable groups, 2 chiefly commercial sex workers and their clients. The prevalence of HIV-1 in India may seem relatively low, at 0.7 percent of the general adult population, compared with rates of 20 percent and higher in Botswana, South Africa, and Zimbabwe. Nevertheless, HIV has now been detected in all states and union territories. It has spread from sex workers and transport workers to women in the general population, and from urban to rural areas. If effective prevention efforts are not implemented and sustained over the long term, mathematical models suggest that India could have over 30 million people infected by 2010 (Nagelkerke and de Vlas 2003) .
The four southern states of Andhra Pradesh, Karnataka, Maharashtra, and Tamil Nadu account for nearly two-thirds of all HIV infections in India, even though they have less than 30 percent of the total population (Table 1) . These four states have among the highest infection rates: a median of 1.3-2.2 percent of women attending antenatal clinics and 14-24 percent of patients attending public facilities for the treatment of sexually-transmitted infections (STI) are infected with HIV-1. The development of a safe and effective preventive AIDS vaccine is becoming a global health priority, particularly in the developing world where HIV is spreading most rapidly. Recent modeling of the impact of an HIV/AIDS vaccine in southern India found that a vaccine that confers 100 percent protection for a lifetime in 95 percent of all vaccine recipients could almost eradicate HIV-1 within 25 years (Nagelkerke and de Vlas 2003) . The impact of a highly effective vaccine would be high, even if commercial sex workers (CSW) and their clients discontinued condom use ("disinhibition"). If high-risk populations were targeted with such a vaccine and assuming disinhibition, adult HIV-1 prevalence in southern India in 2033 would reach 1.4 percent, while it would rise to 2.1 percent if the general population were targeted.
3 On the other hand, a vaccine that confers 50 percent protection in 50 percent of recipients would have less of an impact and preventing disinhibition would be key. Assuming no disinhibition, adult HIV-1 prevalence would reach 3.7 percent in 2033 if high-risk groups are targeted with this less-effective vaccine, and 4.6 percent if the general population is targeted. The effects of this less-effective vaccine could be reversed by disinhibition, with adult HIV-1 prevalence in 2033 of 10.3 percent if high-risk groups are targeted with the vaccine and 10.0 percent if the general population is targeted.
A brainstorming session on HIV-1 vaccine development by India was held in New Delhi in November 1998 among scientists working on an HIV-1 vaccine in India and abroad (World Bank 1999) . All of the experts were of the view that India should initiate a program on HIV-1 vaccine development in collaboration with international scientists, keeping in view the various aspects of clinical trials and ethical issues. Subsequent meetings have resulted in the drafting of a Memorandum of Understanding between the International AIDS Vaccine Initiative and the Government of India represented by the Indian Council of Medical Research (ICMR) and the National AIDS Control Organization (NACO) for accelerating development of an AIDS vaccine applicable for use in India (IAVI website: http://www.iavi.org/highlights/82/oldH2001-03-20_India_VDP_Launch.htm).
Experience with Other Vaccines in India
The experience of the implementation of the routine childhood immunization program in India provides valuable lessons for the introduction of an AIDS vaccine. Even though early generation HIV-1 vaccines may not be suitable for use with children under five, the coverage and service delivery modalities help in understanding the scope of the challenge of introducing a new vaccine in the Indian context. India started with a Universal Immunization Program for children under 5 years of age in the 1970s, then went on to a phase of the Expanded Program of Immunization (EPI), which has become a part of the Reproductive and Child Health (RCH) program. The RCH program includes not only immunization against the six vaccine preventable diseases for children, 4 but also tetanus toxoid for adolescent girls and pregnant women. It further includes some experiments with neo-natal tetanus and hepatitis-B immunization in Andhra Pradesh state.
5
The Indian Academy of Paediatrics has advocated the use of hepatitis B vaccine as part of the routine immunization schedule. Many doctors in the private sector, therefore, do administer hepatitis B vaccine to patients and children under their care. In addition, several schools and non-governmental organizations have been organizing hepatitis B vaccine drives on a payment basis. However, this vaccine has not yet reached the poorer populations, whether urban or rural. The Government of India does support planned state programs for the introduction of the hepatitis B vaccination as part of the routine immunization program. The states of Kerala, Haryana, Delhi, and Andhra Pradesh are all piloting hepatitis B, with the largest coverage (about a third of the state) in Andhra Pradesh.
6 During the recent past, hepatitis B vaccine has been generally available in the private sector hospitals in the urban areas to those who can afford it.
A key lesson from a review of the addition of new vaccines like Hepatitis B and Haemophilus influenza type b in Asia suggests that strengthening routine immunization programs can raise the coverage for newer vaccines and that introduction of newer vaccines can stimulate broader coverage of existing immunization programs (Olivera-Cruz and others 4 BCG, Diptheria-Pertussis-Tetanus (DPT), OVC, measles.
5 India has hepatitis B surface antigen (HbsAg) prevalence between 2 and 10 percent among the populations studied and prevalence does not vary significantly by the different regions of the country. More than 40 million Indians are estimated to be carrying HbsAg. Of the estimated 25 million babies born every year, over one million run the lifetime risk of developing chronic hepatitis B virus (HBV) infection. Estimates also indicate that annually over 100,000 Indians die due to illness related to HBV infection (Lodha and others 2001 
Assessing the Size of Potential Target Groups for an HIV Vaccine
The following section estimates the size of target groups for a public HIV-1 vaccination program in both high-risk groups and the general population. We assume that one strategy for delivering the vaccine would be to piggyback an HIV immunization program on existing programs to reach different groups. Thus, the section also examines the levels of coverage of existing HIV-1 prevention interventions for high-risk groups and the general population in the southern states, highlighting the gaps in coverage.
Analysis shows that targeting high-risk groups with a vaccine is much more costeffective than targeting the entire adult population, regardless of risk (Nagelkerke and de Vlas 2003) . At approximately one third of the number of vaccines needed, a higher reduction in prevalence is achieved. However, this would depend on the type of vaccine developed. Early vaccines may be less than fully effective and of unknown duration. In that case, the vaccine may at best delay infection of high-risk groups and it would be more effective for government to promote condoms and behavior change interventions. On the other hand, highly effective vaccines could potentially be targeted to CSWs only. Vaccinating the general population or clients of CSWs would be less necessary, although it would protect clients against infected CSWs, and the general population from clients who are already infected. Table 2 presents estimates of the size of potential high-and low-risk groups who could be targeted for a preventive HIV-1 vaccine in southern India. Estimates of the number of sex workers in the four states are in the range of 690,000-870,000 and the number of truck drivers roughly double that number. In contrast, the number of sexually transmitted infection (STI) patients in the four states in 2001 was only on the order of 165,000. The four southern states account for about 36 percent of the total STIs recorded in the country at public facilities (see Annex Table 1. 3). However, this is a severe underestimate of the true number of persons with STIs in the population, as more than half of those with symptomatic STIs self-treat or consult private care and others have asymptomatic infections (often the case with women) and thus do not seek treatment. Reliable data on the incidence and prevalence of STIs is limited, mainly due to the inadequacy of the surveillance system (Hawkes and Santhya 2001) . NACO estimates that the annual incidence of STIs is 5 percent of the adult population, which implies that about 7 million new STI cases are occurring annually in the southern states. There is very likely some overlap between the STI patients at government clinics and other high-risk groups, but government clinics with STI services is clearly one way that government can access these groups. A strategy that focused on vaccinating these three high-risk groups in the four states might therefore require on the order of 2.6 million doses of vaccine. While vaccination of low-risk populations will not prevent many secondary infections, if the vaccine is extremely inexpensive to deliver to low-risk groups (relative to delivery to high-risk groups) and/or if there are risks of inhibition among high-risk groups that will reduce the impact of vaccination, then vaccination strategies might target low-risk populations. If resources were available to vaccinate all adults 15-49, then 141 million doses would be necessary. However, it isn't clear how this entire population could be reached. There are more accessible sub-sets of the low-risk population -children under six, adolescents in the 10-14 age group, and women attending antenatal clinics. Current coverage of immunization for children is the base upon which an HIV vaccine could be introduced. This would require about 45 million doses, assuming a single dose per child and current coverage of 83 percent (see Table 3 ). Similarly, about 5 million women in the four states attend ANC clinics. But coverage is lower at 76 percent. Reaching all ANC women would require about 7 million doses The estimates in Table 2 represent the size of the total unvaccinated population of different groups, were the vaccine introduced in 2002. Once the initial groups are covered, the HIV vaccination program will require only sufficient vaccine to 'maintain' coverage levels as individuals join the cohort or group.
The estimates in Table 2 are high-end estimates because it is doubtful that everyone in a given target group could be reached. If the HIV vaccine were distributed via a strategy of piggybacking on existing health interventions, then the coverage of those other interventions or programs provides an alternative estimate of the number of people who could actually be reached. Estimates of estimated levels of coverage of the target populations with current HIV prevention and other services that might serve as conduits for vaccine delivery are in Table 3 . Current coverage of high-risk groups with programs is relatively low-less than a thirdwhile the coverage of many of the low-risk groups (young children via EPI and antenatal care) is relatively high-better than 70 percent. This underscores the point that unless coverage of high-risk groups with other interventions is expanded, an HIV vaccination campaign might have limited access to those most vulnerable to infection. b. Percent of those with an STI in the past 12 months who were treated at a government hospital or clinic, from the 2001 national Behavioral Surveillance Survey (BSS). Note, however, that the sample size of persons reporting an STI was small (ranging from 59 in Tamil Nadu to 288 in Andhra Pradesh), so these estimates are not precise. c. Percent "fully immunized", with BCG, DPT (3 doses), OPV (3 doses), and measles. d. Percent of married women of reproductive age (MWRA) who are using condoms for contraception. Source: See calculations and sources in Annex 1.
Strategic Use of an HIV-1 Vaccine
Currently, in the absence of a vaccine, the prevention strategy is based chiefly on interventions that reduce cascade transmission among and from vulnerable risk groups others 2001, Brunham and Plummer 1990) . Each infection prevented among sex workers prevents "downstream" consequences. Vulnerable-group interventions involve peer-based education of sex workers, their clients and others at high risk (e.g. truck drivers) in the use of condoms, negotiation skills and treatment of STIs. Worldwide experience has found these interventions to be effective.
The HIV-1 vaccine could be delivered either by using the model established by the EPI program, for example, if it is to be targeted to the general population; or by piggybacking on other interventions to reach high-risk groups; or on some combination of these two methods. The vaccine could be made available through the government health care network. In this case, ensuring access to vaccination sites and consistent availability of services are important considerations. Table 4 summarizes delivery strategies for reaching specific low-and high-risk populations with an AIDS vaccine, the size of the groups in southern India, the coverage of the programs, and the strengths and weaknesses of targeting each group via the proposed strategy.
Delivery strategies for the general (low-risk) population
If the vaccine were to be targeted to the general population, then it is useful to look at other programs targeted to this group and how they have performed. Whether the HIV-1 vaccine is administered to newborns or to pre-pubescent youth, lessons could be learned from one of the programs described below in terms of strategies that might be appropriate for dissemination of such a vaccine.
Children under six: Expanded program of immunization. The EPI has a well articulated service delivery network within the public health care system and is provided at all government health facilities: hospitals, primary health centers and sub-centers. In addition to immunization provided at all times to those who attend the health facility, the routine immunization program uses a fixed place and time strategy for outreach. In rural areas, the area covered by a sub-center is divided into four sub-sectors. A UNICEF cluster survey found that about 80 percent of all children between 13-24 months of age were within half a kilometer distance of a scheduled session site. Each sub-sector is served by the sub-center itself, and an outreach session (camp) is planned each month at a selected site on a fixed day of the week. In remote rural areas, a camp approach is used, with health staff and vaccines visiting the area regularly for a three-month cycle twice a year. In the case of the pulse polio immunization campaign, the entire primary health care network is mobilized twice a year, with the necessary infrastructure and supplies carefully planned, to deliver services across the country.
The campaign approach may not be appropriate or feasible for an HIV-1 vaccine, however. Even with a universally accepted program such as polio eradication, there is considerable "camp fatigue" that has set in after 4 years of the pulse polio immunization campaign. In the case of an HIV-1 vaccine, with the social stigma associated with HIV/AIDS, it is likely that the resentment against such campaigns would be even more acute. A much more appropriate method for reaching vulnerable populations would be to use existing intervention programs as an outreach vehicle. Children 11-14: School plus outreach programs. Vaccinating children in the 11-14 age group has the advantage of reaching adolescents shortly before they become sexually active; even a vaccine of less than lifetime duration will have an impact. However, access to these children is limited to school-based programs or community campaigns. There is also a possibility that a short duration vaccine may not protect them during most sexually active years. Notwithstanding this, if vaccinating children 11-14 is promoted as a strategy, then the following issues need to be considered.
India has steadily raised primary enrollment rates since independence and today has the world's second largest education system after China, with 148 million children aged 6-14 attending primary school in 1997 -98 (MOE 2003 . Of these, 39.5 million children are in the upper primary, or 11-14, age group. However, more than 25 million Indian primary schoolage children are not in school. Two out of five first-grade students will not complete the primary cycles of 4 to 5 years (depending on the state), and the learning achievement of those graduating is low. In addition, dropout rates are high: the total dropout rate at primary level for all of India is 39.6 percent, while at upper primary level the rate is even higher at 54.4 percent. The dropout rates for girls are higher--41.3 percent and 58.6 percent, respectively. Children from poorer families are at a greater disadvantage. The dropout rate for the poorest households is about four times that of the richest ones. There are large gaps in access to education; quality of education; and learning according to gender, social class, and location. Even so, with a retention rate at school for children 11-14 of about 46 percent, opportunities for providing school-based interventions for this cohort group are substantial.
Pregnant women: Antenatal clinics. There are about 26 million births annually in India, or about 5 million in the four Southern States. The best measure of antenatal care is the percent that have two tetanus shots in pregnancy. This ranges from 71 to 90 percent in the southern states and is lower elsewhere (IIPS 2000) . Likely the highest risk women do not go to ANCs. An HIV vaccine could be potentially added to the Integrated Child Development Scheme (ICDS). An earlier study found that complete immunization with tetanus toxoid was recorded for 68 percent of the mothers in the those enrolled in the ICDS program but much lower at 40 percent for those not enrolled. Coverage was greater in the urban and lower in the tribal projects. Scheduled castes, scheduled tribes, backward communities, and minorities (groups that have a high priority for social services) had immunization coverage in enrollment areas that were similar to those of higher castes (Tandon and Gandhi 1992) .
Delivery strategies for high-risk groups
Sex workers and truck drivers: Targeted HIV interventions. Targeted interventions comprise a package that includes behavior change communication, condom promotion, STI treatment and creating an enabling environment. NACO and bilateral donors fund between 20 and 114 interventions per state, implemented by nongovernmental organizations (NGOs), that target higher risk people in each of the Southern states. But geographic coverage remains limited, often to just a few districts in each state. Tamil Nadu, with a very active State AIDS Control Society and the USAID-funded AIDS Prevention and Control (APAC) project, has the widest geographic coverage of targeted interventions, but they still are not present in all 30 districts. Until recently, the red-light areas of Mumbai had only two NGOs covering about 3,000 out of 60,000 sex workers. Even with expansion, well over half of sex workers remain outside of NGO programs. Such interventions also lack technical support, operational research, monitoring and evaluation and training to ensure high quality as well as high coverage. Tamil Nadu is a partial exception, and has achieved relatively high coverage of enrolled sex workers and truck drivers; HIV-1 levels appear to show some attenuation (Ramasundaram and others 2001) .
STI patients: Health services. Due to the low coverage of government-run STI clinics (about 30 percent coverage only), NACO has initiated Family Health Awareness Campaigns (FHAC) with the objectives of: (i) making people aware of government services available for the treatment of STDs; (ii) facilitating early detection and prompt treatment of STDs; and (iii) strengthening the capacity of medical and paramedical professionals in the health care system to respond to the HIV epidemic. So far, in the southern states, the FHAC has accomplished the following (Table 5) . STD surveillance through syndrome-based information from peripheral health institutions under the primary health care system and etiological information from STD clinics is due to be introduced, but neither this nor other forms of STI surveillance has yet started (Hawkes and Santhya 2002) .
The Costs of an HIV Vaccination Intervention in Southern India
The cost of the vaccine product mostly reflects fixed costs (R&D and establishing manufacturing capacity); the greater the volume of vaccine procured the lower the unit cost should be. This will make new vaccines even more affordable for poorer countries. In addition, ensuring that "new" vaccines are actually purchased and included in immunization programs will send a strong signal to researchers and manufacturers that future vaccines they develop will have a market with effective demand (Batson and Ainsworth 2001; Loevinsohn 1999) .
In estimating the cost of implementing a publicly-financed HIV-1 vaccination program, we have assumed the following:
• The vaccine would be delivered in a single dose • It would not require refrigeration • It would not confer any benefits to those already infected, but would not be harmful • The cost of the vaccine is Rupees (Rs.) 500 (US$ 10) per dose • At the time that the vaccine is introduced, 1 percent of the 15-49 age group (1.41 million adults at high risk and 80 percent of all children aged 11-14 (21.6 million) would be vaccinated. This would be in line with the current level of coverage of the EPI in the four southern states, and would reflect the combined outcome of school-based and outreach programs.
• Maintaining vaccination rates in these two groups would require vaccination of all entrants to the 11-14 year old cohort/year -in other words, all children turning age 11. We estimate that this is roughly one-fourth of the existing 11-14 cohort (6.77 million children).
• We are making no assumptions about the duration or effectiveness of the vaccine, and assume no wastage and that the potential vaccinees would be willing to be vaccinated-an assumption we revisit in the next section.
The total cost of 21.6 million doses of this vaccine for all adolescents age 11-14 and 1 percent of adults would be Rs. 11.5 billion (US$ 230 million), assuming a vaccine cost of $10/dose. We estimate that the costs of administering the vaccination program in the four states would be equivalent to half of the annual cost of administering the polio eradication program (Rs. 750 million, or US$ 15 million), since polio is administered in 3-doses and requires a cold chain, while the HIV vaccine discussed here is a single dose and does not require refrigeration. The delivery strategy would be similar to the polio program, with a combination of fixed facility and outreach programs. It should be pointed out that these estimates are extremely rough, and would likely underestimate costs quite substantially, since certain fixed costs such as establishment costs, training costs, salaries and so on are not included. The costs are confined to incremental costs associated with administering the vaccine. Thus, the total cost of the initial vaccination ("catch up") of these groups in the four southern Indian states is estimated to cost Rs. 12.25 billion (US$ 245 million). To maintain the vaccination rate in the 11-14 year old cohort, an additional 6.77 million 11-yearolds would have to be vaccinated each year, at a vaccine cost of Rs. 3.39 billion (US $67.5 million). e. Costs of additional condoms only. Assumes that the public sector finances all of the costs of the shortfall in condom use. In fact, a high share of condoms currently used in India is purchased privately through social marketing.
As noted earlier, because of the possibility of using other channels of preventive interventions for delivering an AIDS vaccine, the risk of reversals of other preventive behaviors (disinhibition) with a less than fully effective vaccine, and the complementarities among interventions in increasing knowledge and reducing stigma, introduction of an HIV-1 vaccine would have to occur in parallel with a scaling up of other preventive interventions and of sentinel surveillance. Table 5 summarizes the costs of an AIDS vaccine and total costs of "scaling up" these other HIV preventive interventions in the four states -the vulnerable group interventions for sex workers and truckers, STI treatment, and HIV sentinel surveillance. These estimates, for which the calculations are detailed in Annex 2, are extremely rough and do not include certain fixed costs such as start-up costs, training costs, salaries and so on. The costs are confined to incremental investment and recurrent program costs of the additional interventions necessary for the specified coverage and do not include the recurrent costs of maintaining existing prevention activities.
The investment costs of introducing an AIDS vaccine (under the assumptions made) and achieving full coverage of vulnerable groups, STI treatment, and sentinel surveillance works out to an additional US$0.93 per capita and the recurrent costs to an additional US$ 0.32 per capita per year. This is substantially higher than the US$0.02 -US$0.04 currently being spent in these states, but the current programs do not include an AIDS vaccine and the coverage of the existing interventions is low (Jha and Mills 2002) If one were to add the objective of universal condom use by men in sex within and outside marriage, then the total investment costs rise to US$2.80 per capita and the recurrent cost to US$2.18/capita/ yearassuming that it is entirely financed by the government. The key point from such costing efforts is that a relatively large increase in spending over current levels is required, even if the vaccine cost is as low as Rs. 500 (US$10). It will require considerable political will to make this quantum leap in funding, as well as considerable assistance from bilateral and multilateral donors. In Andhra Pradesh and Karnataka, the current leadership is very keen on tackling the epidemic effectively and making a difference. The Chief Minister of Karnataka, Mr. S.M. Krishna, has personally taken over as the Chairman of the Karnataka AIDS Prevention Society. Such leadership needs to be supported with adequate epidemiological information and programmatic guidance to be able to make the necessary financial commitment.
Key Constraints to Introducing an HIV Vaccine and Scaling-up Prevention
Stigma. Unless the stigma associated with HIV/AIDS in India can be reduced, few individuals will be willing to be vaccinated and the successful expansion of other preventive interventions to high-risk groups will be jeopardized. HIV/AIDS-related stigma and discrimination are most closely related to sexual stigma, since it deals with the sexual behavior of persons who are considered to be different from the "norm" (Population Council 2000) . It is also strongly linked to gender-related stigma: female sex workers are often stigmatized as carriers and vectors of spread of HIV-1 instead of mere links in the broad network of heterosexual transmission. Class distinctions are also related to HIV/AIDS, since poverty increases vulnerability to the infection. Finally, HIV/AIDS is a life threatening illness that people are afraid of contracting. This interacts with other sources of stigma attached to the illness and exacerbates the problem. (Jha and Mills 2002) . However, the CMH costs were for an expanded set of activities that did not include universal condom promotion. The CMH estimates are in line with the estimates that exclude condom promotion in Table 5 .
Low public awareness and ownership: Raising the levels of awareness of people about the modes of transmission of HIV-1 and the methods of prevention needs to be accorded a high priority under the program, a prerequisite for any eventual vaccination program and for the successful expansion of preventive interventions.
Vaccine delivery infrastructure. While the immunization program in India has accomplished a good deal, with a steady decline in the number of vaccine-preventable diseases being reported, overall program performance has been sub-optimal and uneven across states (World Bank 2000) . This has been largely due to an erosion of both human resource and infrastructure capacity. The cold chain, necessary to refrigerate vaccines from procurement to client use, and the transport system have weakened due to aging and inadequate financing. Better coordination is needed among the departments managing the five major components of the program: vaccine production, vaccine quality assurance, service delivery, disease surveillance, and research. As a result, India has been unable to take advantage of the global technological advances that have made available new vaccines, such as hepatitis B. In the absence of national guidelines, states have responded to vaccinepreventable disease with inefficient campaign approaches, as in the case of neonatal tetanus, or by introducing new vaccines on a pilot basis, with insufficient consideration of epidemiological factors, costs, institutional capacity, and sustainability (World Bank 2000).
The public health delivery system. The capacity of the public health system would need to be substantially built up in order to handle an expanded HIV vaccination program. Having well trained field workers in place, especially designated as HIV/AIDS officers, would greatly enhance the effectiveness of the program at the field level. This has been the case in other successful programs that have required intensive community-level intervention such as leprosy elimination, nutrition, and polio eradication. To re-train the network of polio officers, for example, and utilize their services for HIV-1 prevention would be one way of addressing this problem.
Lack of a plan to involve the private sector. Given the size of the private health sector in India and its reach in rural areas, excluding the private sector may severely limit the scope and impact of an HIV vaccination program. In addition, the private sector is believed to be a dominant source of primary treatment of STIs. Involvement of private physicians would help measures, like compulsory screening and testing, compulsory notification of AIDS cases, and isolation and detention of HIV-1 positive persons. Second, at the institutional level, such practices as pre-employment screening, termination of employment of people living with HIV/AIDS (PLWHA), and denial of treatment and care, must not be allowed to occur. Third, stigma must be dealt with in the community context, as local cultural beliefs and practices may blame the individual for contracting the disease. This could lead to scape-goating, punishment and shunning, particularly of those already suffering from AIDS. In some extreme cases, this has lead to AIDS-related murders (recent case in Maharashtra). Finally, stigma must be addressed in the family context, since the family is the major source of care and support. The effect of stigma within the family is most severely experienced by women, who are often rejected by the family and face loss of home and children. The stigmatization can also extend to the larger family of the people living with HIV/AIDS, such as their children and partners.
to enhance the coverage of STI services and provide an opportunity for timely intervention, in particular the syndromic management. Although the immunization program in India requires mainly public sector delivery and financing, the private sector and NGOs have both key roles to play in social mobilization for immunization and in service delivery in areas where the public sector system is weak, in the cities (private sector) and in deprived rural areas (NGOs).
National capacity for vaccine trials. At an operational level, developing countries such as India offer a different set of challenges with respect to vaccine development and field trials. There is a lack of trained investigators (science, clinical trials, ethics, lab, data management, project management) and infrastructure (clinics, labs, equipment, supplies) in place to conduct vaccine trials. The regulatory processes to consider and evaluate proposed experimental vaccine trials are not developed. A formidable challenge in vaccine development is the enormous genetic diversity of HIV-1 found world-wide. Most candidate vaccines are based on HIV clade B, which is only one of more than ten clades and not the one that is dominant in India (NIAID 2000) . An ideal vaccine must protect individuals against any genetic subtype of the virus as well as any route of HIV-1 infection. In addition, it was found in Uganda that participants in vaccine trials feared contracting the infection from the vaccine (Mugerwaa and others 2002).
Inadequate funding for HIV prevention. Low funding for vulnerable group interventions is one constraint to high coverage. NACO is currently funded by a World Bank credit of $191 million over five years. A quarter of this is for targeted interventions to vulnerable groups. 9 In addition, USAID, the UK Department for International Development (DfID), and the Canadian International Development Agency (CIDA) will provide approximately $71 million over the same period, mainly focusing on vulnerable groups. All told, this means approximately 2 US cents per capita per year for prevention of HIV in vulnerable groups, or approximately 12 US cents in purchasing power parity terms. In Karnataka, for example, the budget for targeted interventions for the year 2002-03 is about Rs.12,140,000 (US$245,000), which works out to about 4 US cents per capita. Even with the 20 new interventions planned with an additional expenditure of Rs. 17, 200, 000 (US$350, 000) , this is a woefully inadequate amount to be spending in a state that has an HIV-1 prevalence rate of 1.68percent in ANC sites.
Capacity to design, implement, monitor, and evaluate programs. There is a huge need for capacity building of all levels of workers to design, implement, monitor, and evaluate HIV programs: State AIDS Control Society officers; NGO personnel; field workers; and health workers. Some efforts have worked in different states but they need to be scaled up significantly, and need to be replicated in other states where such initiatives have not yet been undertaken. Current coverage of sentinel surveillance at both ANC sites and STI sites is very low (30 percent and 19 percent, respectively). There is no functioning STI surveillance system in place, and no data on either STI or HIV-1 from the private sector, where the majority of service providers operate. Monitoring and evaluation capacity is extremely weak.. The state with the best record is Tamil Nadu, where sentinel surveillance and six waves of behavioral surveillance sponsored by USAID-funded APAC project have successfully tracked the epidemic, levels of awareness, and behavior change. Such data has helped TNSACS to set priorities for focused interventions. Andhra Pradesh and Karnataka are now beginning to benefit from this type of input from the DfID-and CIDA-funded programs in their states, but much more needs to be done.
Recommendations
This study gives rise to several recommendations. First, there is a need to more indepth case studies on the ability and willingness of various vulnerable groups to accept and access a possible HIV-1 vaccine.
Second, there is a need to expand implementation of prevention programs, which will remain critical even if an effective vaccine is eventually available.
Third, the common inputs to vaccines and prevention require considerable strengthening. These include:
• Better surveillance of the trends in HIV-1 by expanding the number and quality of sentinel surveillance among ANC and STI clinic attendees to every district.
• As sentinel surveillance is poor at predicting levels (it is better at detecting changes in prevalence), a few large, longitudinal studies of well-characterized population cohorts of HIV-1 negative people to measure the incidence of HIV-1 (the number of new infections). These are also required to better understand transmission dynamics in different states and thus help inform the relative importance of targeting vaccines.
• Common tools of mapping at local levels (i.e. district or below) of populations who would require preventive interventions, including vaccines.
• Strong human resource development of a cadre of HIV/AIDS officers who can work like the polio officers in India to: conduct surveillance and improve its quality; work and train NGOs to conduct peer group interventions; and strengthen STI syndromic management.
• Ongoing evaluation activities to identify gaps in coverage (for example, continuously providing denominators of "unreached populations" as do immunization programs) and to help monitor any adverse behavior change that could occur from introduction of vaccines and/or availability of anti-retroviral therapies.
Annex 1. Estimates of the Coverage of Public Health Interventions in Key Groups
Annex NFHS, 1992 -93 and 1998 -99, from IIPS (1995 , 2000 .
Annex 2. Estimating the Costs of Additional Coverage ("scaling up") of HIV Prevention Programs in Southern India
Targeted interventions to high-risk groups
NACO guidelines for costing interventions, which are largely based on experience in some of the southern states, suggest that the annual cost per person reached is Rs. 1,208.05 per CSW and Rs. 94.7 per truck driver (NACO 1999) . Bringing coverage to 100 percent for these two groups would require reaching (approximately) 800,000 additional sex workers (using the high estimates of the number of CSWs in these states) and 1.25 million additional truckers, at a total annual cost of Rs. 966.8 million (US$ 19.3 million) for CSW and Rs. 118.4 million (US $2.4 million) for truckers. These are the annual recurrent costs for the coverage of the additional interventions and exclude training or capacity building to NGOs that would be necessary investments in wider implementation.
STI treatment services
The estimated cost of scaling up an STI control program is based on the costing worked out by the Maharashtra State AIDS Control Society. The cost of raising the number of STI sites per district to two would cost about Rs. 23 million per state or US$0.5 million in investment costs.
10 This would include the costs of goods (Rs. 1.7 million or US$300,000); equipment (Rs. 6.9 million or US$0.15 million); vehicles and furniture (Rs. 1.5 million or US$0.03 million); and medicines (Rs. 12 million or US$0.25 million). The recurrent costs per state for these additional STI clinics would be about Rs. 14 million or US$0.3 million. Together across the four states, this amounts to investment costs of Rs. 92 million (US$ 1.8 million) and annual recurrent costs of Rs. 56 million (US$ 1.1 million) for the additional clinics.
Sentinel surveillance
In order to establish a minimum of one sentinel surveillance site in each district, an additional 59 sentinel sites need to be set up. An estimate made by the Karnataka State AIDS Control Society in their Action Plan indicates that an additional sentinel site would cost Rs. 110,000 (honorarium for personnel, transportation, training and equipment). The cost of 59 additional sites would amount to Rs. 6,490,000 or US$130,000.
Condom distribution
The total population of adults 15-49 in the four states is roughly 140 million, of which roughly half, or 70 million, are men (see Table 2 of the text). If one were to establish the goal of condom use in every sexual act (including universal condom use in marriage, even if one partner is already sterilized) and assuming an average need of 100 condoms per man per year, then the total requirements for condom distribution (through public or private sources) would be 7 billion condoms.
For fiscal year 1999-200, distribution of condoms in the southern states through NACO (including socially marketed condoms and those commercially distributed) is estimated to be 25 percent of the national total of roughly 650 million condoms, or 162.5 million. In addition, about 80 million condoms are distributed free of charge in these states through the Ministry of Health and Family Welfare. This brings the total current distribution to 242.5 million condoms annually.
The shortfall between actual condom distribution and 100 percent coverage is therefore 6.76 billion condoms. At Rs. 4 per condom, the total cost would be about Rs. 27 billion or US$ 540.6 million a year.
Due to the low usage rates of condoms, the concern is whether the distribution under RCH and AIDS control is enough and whether it should be scaled up to cover all the persons in the target cohort or restricted to a lesser percentage with a suitable effort to increase social marketing and commercial distribution. Over the years, condoms have become associated with family planning, and couples who have chosen more permanent methods such as vasectomy or tubal ligation would not feel it necessary to use condoms. To promote condoms for reasons other than family planning would take a particularly rigorous behavior change communication program aimed at the general population. NACO figures indicate that twice the number of condoms was being socially and commercially marketed in the southern states as was freely distributed, indicating that there is a willingness to pay for condoms among certain segments of the population. However, this may not apply to all segments. These are some of the concerns that need to be addressed.
